BREAKWATER Supports FDA Approval of Encorafenib-Cetuximab-FOLFIRI for BRAF V600E-Mutant mCRC

Rákkutatás · Colorectal cancer · BRAF

Encarnafenib plus cetuximab with FOLFIRI significantly improves progression‑free and overall survival compared with FOLFIRI ± bevacizumab as first‑line therapy in patients with BRAF V600E‑mutant metastatic colorectal cancer.

This phase 3 randomized trial demonstrated that encorafenib plus cetuximab with FOLFIRI improves progression‑free and overall survival versus FOLFIRI ± bevacizumab in first‑line treatment of BRAF V600E‑mutant metastatic colorectal cancer.

These findings support FDA approval, offering a more effective first‑line therapy for a subset of metastatic colorectal cancer patients with limited treatment options.

Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.

Eredeti forrás

Kapcsolódó jelek